CNS Pharmaceuticals, Inc. (CNSP)

Market Cap	6.01M
Revenue (ttm)	n/a
Net Income (ttm)	-15.61M
Shares Out	5.46M
EPS (ttm)	-14.69
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	196,688
Open	1.150
Previous Close	1.145
Day's Range	1.070 - 1.160
52-Week Range	0.772 - 800.000
Beta	0.77
Analysts	Hold
Price Target	n/a
Earnings Date	May 16, 2025

About CNSP

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company’s lead drug candidate TPI 287 and Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma and other CNS malignancies. CNS Pharmaceuticals, Inc. has license agreements with Houston Pharmaceuticals, Inc., Cortice Biosciences, Inc., and The University of Texas M.D. Anderson Cancer Center, as well as a collaboration a...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 8, 2019
• Employees: 5
• Stock Exchange: NASDAQ
• Ticker Symbol: CNSP
• Website: https://www.cnspharma.com